1
Paul J Carter, Leonard G Presta: Immunoglobulin variants. Genentech, Wendy M Lee, October 13, 1998: US05821337 (544 worldwide citation)

Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.


2
Paul J Carter, Leonard G Presta: Humanized antibodies and methods for making them. Genentech, Wendy M Lee, April 25, 2000: US06054297 (468 worldwide citation)

Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.


3
Leonard Presta: Polypeptide variants with altered effector function. Genentech, Wendy M Lee, May 18, 2004: US06737056 (440 worldwide citation)

The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.


4
Paul J Carter, Leonard G Presta: Method for making humanized antibodies. Genentech, Wendy M Lee, June 18, 2002: US06407213 (392 worldwide citation)

Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.


5
Esohe Ekinaduese Idusogie, Leonard G Presta, Michael George Mulkerrin: Polypeptide variants. Genentech, Wendy M Lee, February 27, 2001: US06194551 (344 worldwide citation)

A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at amino acid position 329, or at two or all of amino acid positions 329, 331 and 322 of the human IgG Fc region. Such variants display altered effector function. For example, ...


6
Xanthe M Lam, James Q Oeswein, Boonsri Ongpipattanakul, Zahra Shahrokh, Sharon X Wang, Robert P Weissburg, Rita L Wong: Antibody formulation. Genentech, Lee K Tan, Wendy M Lee, January 9, 2001: US06171586 (289 worldwide citation)

A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.5 to about 6.0, a surfactant and a polyol is described, along with uses for such a formulation.


7
James Andya, Jeffrey L Cleland, Chung C Hsu, Xanthe M Lam, David E Overcashier, Steven J Shire, Janet Yu Feng Yang, Sylvia Sau Yan Wu: Protein formulation. Genentech, Wendy M Lee, July 31, 2001: US06267958 (272 worldwide citation)

A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared ...


8
Robert M Hudziak, H Michael Shepard, Axel Ullrich, Brian M Fendly: Monoclonal antibodies directed to the HER2 receptor. Genentech, Wendy M Lee, October 14, 1997: US05677171 (253 worldwide citation)

Monoclonal antibodies which bind to the extracellular domain of the HER2 receptor and inhibit growth of SK-BR-3 breast tumor cells, which overexpress HER2, are disclosed. The monoclonal antibodies can be used for in vitro assays for detecting a tumor characterized by amplified expression of HER2.


9
Ernst H Rinderknecht, Gerardo A Zapata: Low pH hydrophobic interaction chromatography for antibody purification. Genentech, Wendy M Lee, June 24, 1997: US05641870 (241 worldwide citation)

A process for purifying an antibody is provided. In this process, a mixture containing the antibody and contaminant is subjected to low pH hydrophobic interaction chromatography (LPHIC) optionally at low salt concentration. The antibody is eluted from the column in the fraction which does not bind t ...


10
Paul J Carter, Leonard G Presta, John B Ridgway: Method for making heteromultimeric polypeptides. Genentech, Wendy M Lee, March 24, 1998: US05731168 (236 worldwide citation)

The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves introducing a protube ...